ORLANDO — Genetic testing is warranted in patients with epilepsy of unknown origin, new research suggests. Investigators found that pathogenic genetic variants were identified in over 40% of patients ...
Please provide your email address to receive an email when new articles are posted on . The study included 250 patients with epilepsy. A history of delayed development and earlier seizure onset were ...
STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
Noninvasive tests performed in midlife may help identify people who are at risk of late-onset epilepsy (LOE), a new study suggests. New data from the Framingham Heart Study show those who scored ...
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
Investor's Business Daily on MSN
Will This Genetic Testing Name's Profit Soar 950%? Earnings Are On Deck.
This medical services stock is nearing a buy point. It has shown tremendous profit growth over the last few quarters.
The University of Utah College of Pharmacy's Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $19.5 million contract renewal with the National Institutes of Health (NIH) to ...
NEW HAVEN, Conn. (KABC) -- Every state has different requirements when it comes to driving with epilepsy. Here in California, patients must be seizure-free for a specific period of time and submit a ...
A team led by the UAB Institut de Neurociències (INc-UAB) has for the first time identified the mechanism behind a ...
The Patient Access Program helps to ensure more equitable care across pediatric epilepsy populations. Exome testing is recommended as a first-line test for patients with unexplained epilepsy by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback